posted on 2021-02-19, 22:01authored byChristian Herder, Haifa Maalmi, Klaus Strassburger, Oana-Patricia Zaharia, Jacqueline M. Ratter, Yanislava Karusheva, Mohamed A. Elhadad, Kálmán Bódis, Brenda W. C. Bongaerts, Wolfgang Rathmann, Sandra Trenkamp, Melanie Waldenberger, Volker Burkart, Julia Szendroedi, Michael Roden, GDS Group
A novel clustering approach identified five
subgroups of diabetes with distinct progression trajectories of complications.
We hypothesized that these subgroups differ in multiple biomarkers of
inflammation. Serum levels of 74 biomarkers of inflammation were measured in
414 individuals with recent adult-onset diabetes from the German Diabetes Study
(GDS) allocated to five subgroups based on data-driven analysis. Pairwise
differences between subgroups for biomarkers were assessed with generalized
linear mixed models before (model 1) and after adjustment (model 2) for the clustering variables.
Participants were assigned to five subgroups: severe autoimmune diabetes
(SAID, 21%), severe insulin-deficient diabetes (SIDD, 3%), severe
insulin-resistant diabetes (SIRD, 9%), mild obesity-related diabetes (MOD, 32%)
and mild age-related diabetes (MARD, 35%). In model 1, 23 biomarkers showed ≥1 pairwise
difference between subgroups (Bonferroni-corrected p<0.0007). Biomarker levels were generally highest in SIRD
and lowest in SIDD. All 23 biomarkers correlated with ≥1 of the clustering variables.
In model 2, three biomarkers (CASP-8, EN-RAGE, IL-6) showed at least one
pairwise difference between subgroups (e.g. lower CASP8, EN-RAGE and IL-6 in SIDD
vs. all other subgroups, all p<0.0007).
Thus, novel diabetes subgroups show multiple differences
in biomarkers of inflammation, underlining a prominent role of inflammatory
pathways in particular in SIRD.
Funding
The German Diabetes Study (GDS) was initiated and financed by the German Diabetes Center, (DDZ) which is funded by the German Federal Ministry of Health (Berlin, Germany), the Ministry of Culture and Science of the state North Rhine-Westphalia (Düsseldorf, Germany), and grants from the German Federal Ministry of Education and Research (Berlin, Germany) to the German Center for Diabetes Research e.V. (DZD).